Vortex Biotech opens new state-of-the-art laboratory at Manchester Science Park
Expansion accelerates the development of its non-invasive cancer diagnostic solutions
ProImmune introduces Mastering Immunity 2026 - Shanghai Symposium to address key immunogenicity challenges
Symposium brings together global leaders in immunogenicity to connect with China’s rapidly evolving pharmaceutical development landscape Speakers include thought leaders in biotherapeutics, complex peptide drug developers, and regulatory authoritiesIn-SPT Labtech enables automated Twist Bioscience NGS library preparation workflows on SPT’s firefly platform
Automated Twist NGS library preparation workflows available on SPT Labtech’s firefly platform via the firefly cloud Validated methods support Twist FlexPrep™ UHT and Enzymatic Fragmentation Kit 2.0, enabling higher throughput and reproducibility in NGS library preparatiAxol Bioscience raises $2.8M to advance US expansion and product development
Financing led by US life sciences investor, BroadOak Capital Partners Investment to support expansion of US operations, product development, and cell manufacturing scale-upCambridge / Edinburgh, UK, 13th January 2026: Axol B
Optibrium appoints Dr Nathan Brown as Director of Science
Newly created role underscores commitment to customer-driven research and scientific excellence
OutSee completes seed funding round and establishes partnership with o2h discovery for lead drug target candidate
Oversubscribed £2.5M seed round led by Ahren Innovation CapitalStrategic collaboration with o2h to progress drug discovery programmeCambridge, UK, 12 January 2026: OutSee, a genomics and drug discovery company pioneering a unique AI-ba
iXCells Biotechnologies appoints Steve Smith as CEO
Appointment strengthens leadership team as iXCells focuses on expanding its portfolio of custom-tailored iPSC products and delivery of enhanced preclinical services
FairJourney Bio launches cryo-EM services with advanced laboratories in San Diego, USA
Expanded offering provides high-resolution structural insights to support antibody discovery and biologic design
Qureight appoints Rebecca Simmons as Chief Operating Officer
Experienced operational leader across medical research and deep tech appointed to support sustainable growth as part of Qureight’s strategy to scale company operations
Enhanced Genomics appoints Dr Katerina Leftheris to its Board of Directors
Experienced leader in preclinical and clinical drug development will support expansion of Company’s therapeutics pipeline for complex and common genetic diseases
FairJourney Bio to present at J.P. Morgan 2026 Healthcare Conference
PORTO, Portugal, 08 January, 2026 – FairJourney Bio (FJBio), a global leader in antibody discovery and development, announced today that its Chief Executive Officer, Dr. Werner Lanthaler, will present at the J.P.
Qureight appoints Dr Steven Bishop as Chief Medical Officer
Change in role from Chief Data Officer reflects Qureight’s continued growth and commercial success in delivering customers’ clinical studies
FUJIFILM Irvine Scientific now officially FUJIFILM Biosciences
Rebrand announced in June as part of Fujifilm Life Sciences Group restructuring becomes official
CHITOSE and FUJIFILM Biosciences Form Strategic Alliance to Drive Global Innovation and Biopharmaceutical Manufacturing
Collaboration formed to accelerate biopharmaceutical manufacturing combining high performing CHO-MK cells and GMP-manufactured culture media
Atelerix enters agreement with Cherry Biotech to integrate non-cryogenic transport solutions with advanced organoid models
Partnership brings together proven non-cryogenic biosample preservation technology and advanced organoid models to support growth in preclinical research and biotech sectors
EpilepsyGTx raises $33 million Series A to develop single dose gene therapy for focal refractory epilepsy
Investment from XGEN Venture, British Business Bank, and a global biopharmaceutical company will support first-in-human Phase 1/2a clinical trials for lead candidate EPY201 targeting focal refractory epilepsy (FRE)Future financings to advance a pipeline of transformativVALANX Biotech establishes Board of Directors
Renowned industry leaders, Michael Boehler, Alexander Schwartz, Urs Spitz and Ingo Nagler, appointed to guide strategic and commercial development
Enterprise Therapeutics publishes results of Phase 1 study of ETD001, a novel inhaled ENaC blocker for treatment of Cystic Fibrosis, in The Journal of Cystic Fibrosis
ETD001 is well tolerated in healthy individuals at higher doses than predicted to be therapeutic for long-lasting enhancement of mucociliary clearanceResults showed excellent consistency between preclinical and clinical behaviour of ETD001Phase 2 trialLab Thread announces Beta release of Unified Lab Software Platform
Designed to streamline collaboration across biological research, combining real-time data management, analysis, DNA sequence design, chat and review functions within one intuitive, easy to use systemInterested parties invited to register for beta access via the Lab ThreTRIMTECH Therapeutics appoints Alison Lawton as Chair of the Board
Experienced biotech Chair and executive will guide corporate growth and development
Atelerix and Labskin partner to enable long-distance transport of advanced in vitro skin models
Agreement to broaden access, streamline logistics, and reduce variability associated with temperature-sensitive shipping of 3D tissue models, without cryopreservationJoint webinar to present trial performance data and best-practice workflows for global research communitOBN Awards 2025 celebrate the most exciting innovations and inspiring achievements happening across the Life Sciences industry
Abingdon, UK, 27 November 2025: – OBN (UK) Ltd, the membership organisation whose mission is to catalyse success in the life science industry, is thrilled to announce the winners of the 17th annual OBN Awards, an evening organised by